一线指南,助力战“疫” Military Medical Research发表新型冠状病毒感染的肺炎诊疗指南
时间:2020-02-20 来源:本站 作者:
论文标题:A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
期刊:Military Medical Research
作者:Ying-Hui Jin, Lin Cai et al.
发表时间:2020/02/06
DOI:10.1186/s40779-020-0233-6
微信链接:点击此处阅读微信文章
Military Medical Research 于2020年2月6日发表 A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (Standard version)(《新型冠状病毒(2019-nCoV)感染的肺炎诊疗快速建议指南(标准版)》)。该指南遵照WHO快速建议指南方法学、融合临床一线诊治经验,围绕2019-nCoV的病因、防控、诊断、治疗和护理展开。
In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named 2019 novel coronavirus (2019-nCoV) by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.